Capula Management Ltd Purchases New Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Capula Management Ltd acquired a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the 4th quarter, HoldingsChannel reports. The firm acquired 8,574 shares of the specialty pharmaceutical company’s stock, valued at approximately $310,000.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in Supernus Pharmaceuticals by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 6,150,759 shares of the specialty pharmaceutical company’s stock valued at $222,411,000 after buying an additional 22,852 shares during the last quarter. Geode Capital Management LLC lifted its stake in Supernus Pharmaceuticals by 1.9% in the fourth quarter. Geode Capital Management LLC now owns 1,510,568 shares of the specialty pharmaceutical company’s stock worth $54,633,000 after acquiring an additional 28,517 shares during the last quarter. American Century Companies Inc. lifted its position in shares of Supernus Pharmaceuticals by 9.2% during the 4th quarter. American Century Companies Inc. now owns 1,140,705 shares of the specialty pharmaceutical company’s stock worth $41,248,000 after purchasing an additional 95,777 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Supernus Pharmaceuticals by 5.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 753,363 shares of the specialty pharmaceutical company’s stock worth $27,242,000 after buying an additional 40,968 shares during the last quarter. Finally, Invesco Ltd. lifted its stake in Supernus Pharmaceuticals by 4.5% during the fourth quarter. Invesco Ltd. now owns 508,069 shares of the specialty pharmaceutical company’s stock worth $18,372,000 after purchasing an additional 22,027 shares during the last quarter.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of the firm’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the transaction, the senior vice president now directly owns 7,853 shares in the company, valued at approximately $307,444.95. This trade represents a 10.56 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Padmanabh P. Bhatt sold 700 shares of the stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total value of $27,734.00. Following the sale, the vice president now owns 10,149 shares in the company, valued at approximately $402,103.38. This trade represents a 6.45 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,104 shares of company stock valued at $440,263 in the last quarter. 9.30% of the stock is currently owned by corporate insiders.

Supernus Pharmaceuticals Stock Down 1.4 %

Shares of SUPN opened at $32.27 on Tuesday. Supernus Pharmaceuticals, Inc. has a 52-week low of $25.53 and a 52-week high of $40.28. The company has a market capitalization of $1.80 billion, a PE ratio of 30.16 and a beta of 0.90. The company has a 50-day simple moving average of $34.42 and a 200-day simple moving average of $35.08.

Analyst Upgrades and Downgrades

SUPN has been the subject of several research analyst reports. StockNews.com upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, April 1st. Cantor Fitzgerald reiterated a “neutral” rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.